Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial

{ 'indexed': {'date-parts': [[2024, 6, 15]], 'date-time': '2024-06-15T17:19:40Z', 'timestamp': 1718471980793}, 'reference-count': 25, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2024, 1, 1]], 'date-time': '2024-01-01T00:00:00Z', 'timestamp': 1704067200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 11, 21]], 'date-time': '2023-11-21T00:00:00Z', 'timestamp': 1700524800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': { 'domain': ['thelancet.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2024, 1]]}, 'DOI': '10.1016/j.eclinm.2023.102359', 'type': 'journal-article', 'created': { 'date-parts': [[2023, 12, 15]], 'date-time': '2023-12-15T00:02:30Z', 'timestamp': 1702598550000}, 'page': '102359', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a ' 'multicentre randomised, double-blind, placebo-controlled phase 3 trial', 'prefix': '10.1016', 'volume': '67', 'author': [ {'given': 'Yangqing', 'family': 'Zhan', 'sequence': 'first', 'affiliation': []}, {'given': 'Zhengshi', 'family': 'Lin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jingyi', 'family': 'Liang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ruilin', 'family': 'Sun', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yueping', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bingliang', 'family': 'Lin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fangqi', 'family': 'Ge', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ling', 'family': 'Lin', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8308-5534', 'authenticated-orcid': False, 'given': 'Hongzhou', 'family': 'Lu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Liang', 'family': 'Su', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tianxin', 'family': 'Xiang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hongqiu', 'family': 'Pan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chaolin', 'family': 'Huang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ying', 'family': 'Deng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Furong', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ruhong', 'family': 'Xu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dexiong', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ping', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jianlin', 'family': 'Tong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xifu', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Qingwei', 'family': 'Meng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhigang', 'family': 'Zheng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shuqiang', 'family': 'Ou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xiaoyun', 'family': 'Guo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Herui', 'family': 'Yao', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tao', 'family': 'Yu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Weiyang', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yu', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7393-2664', 'authenticated-orcid': False, 'given': 'Mei', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhonghao', 'family': 'Fang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yudi', 'family': 'Song', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ruifeng', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jincan', 'family': 'Luo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Changyuan', 'family': 'Kang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shiwei', 'family': 'Liang', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0009-0007-7432-8454', 'authenticated-orcid': False, 'given': 'Haijun', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jingping', 'family': 'Zheng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nanshan', 'family': 'Zhong', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-2681-4171', 'authenticated-orcid': False, 'given': 'Zifeng', 'family': 'Yang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Huang', 'family': 'Yanming', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dong', 'family': 'Haiping', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jinlin', 'family': 'Hou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shao', 'family': 'Lei', 'sequence': 'additional', 'affiliation': []}, {'given': 'Li', 'family': 'Xiaoguang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gao', 'family': 'Yan', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '6538', 'key': '10.1016/j.eclinm.2023.102359_bib1', 'first-page': '372', 'article-title': 'Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in ' 'England', 'author': 'Davies', 'year': '2021', 'journal-title': 'Science'}, { 'issue': '7898', 'key': '10.1016/j.eclinm.2023.102359_bib2', 'doi-asserted-by': 'crossref', 'first-page': '657', 'DOI': '10.1038/s41586-021-04385-3', 'article-title': 'Omicron escapes the majority of existing SARS-CoV-2 neutralizing ' 'antibodies', 'volume': '602', 'author': 'Cao', 'year': '2022', 'journal-title': 'Nature'}, { 'issue': '7923', 'key': '10.1016/j.eclinm.2023.102359_bib3', 'doi-asserted-by': 'crossref', 'first-page': '593', 'DOI': '10.1038/s41586-022-04980-y', 'article-title': 'BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron ' 'infection', 'volume': '608', 'author': 'Cao', 'year': '2022', 'journal-title': 'Nature'}, { 'issue': '5', 'key': '10.1016/j.eclinm.2023.102359_bib4', 'doi-asserted-by': 'crossref', 'first-page': '860', 'DOI': '10.1016/j.cell.2022.01.019', 'article-title': 'Structural and functional characterizations of infectivity and immune ' 'evasion of SARS-CoV-2 Omicron', 'volume': '185', 'author': 'Cui', 'year': '2022', 'journal-title': 'Cell'}, { 'issue': '7923', 'key': '10.1016/j.eclinm.2023.102359_bib5', 'doi-asserted-by': 'crossref', 'first-page': '603', 'DOI': '10.1038/s41586-022-05053-w', 'article-title': 'Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and ' 'BA.5', 'volume': '608', 'author': 'Wang', 'year': '2022', 'journal-title': 'Nature'}, { 'issue': '7948', 'key': '10.1016/j.eclinm.2023.102359_bib6', 'first-page': '521', 'article-title': 'Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD ' 'evolution', 'volume': '614', 'author': 'Cao', 'year': '2023', 'journal-title': 'Nature'}, { 'key': '10.1016/j.eclinm.2023.102359_bib7', 'series-title': 'Therapeutic management of nonhospitalized adults with COVID-19', 'author': 'NIH', 'year': '2022'}, { 'issue': '6575', 'key': '10.1016/j.eclinm.2023.102359_bib8', 'doi-asserted-by': 'crossref', 'first-page': '1586', 'DOI': '10.1126/science.abl4784', 'article-title': 'An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the ' 'treatment of COVID-19', 'volume': '374', 'author': 'Owen', 'year': '2021', 'journal-title': 'Science'}, { 'issue': '5', 'key': '10.1016/j.eclinm.2023.102359_bib9', 'doi-asserted-by': 'crossref', 'first-page': '585', 'DOI': '10.1007/s40265-022-01692-5', 'article-title': 'Nirmatrelvir plus ritonavir: first approval', 'volume': '82', 'author': 'Lamb', 'year': '2022', 'journal-title': 'Drugs'}, { 'issue': '4', 'key': '10.1016/j.eclinm.2023.102359_bib10', 'doi-asserted-by': 'crossref', 'first-page': '1387', 'DOI': '10.1007/s00467-022-05712-0', 'article-title': 'Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir ' '(Paxlovid) for COVID-19 infection in a child with a kidney transplant', 'volume': '38', 'author': 'Young', 'year': '2023', 'journal-title': 'Pediatr Nephrol'}, { 'key': '10.1016/j.eclinm.2023.102359_bib11', 'doi-asserted-by': 'crossref', 'first-page': '305', 'DOI': '10.1053/j.gastro.2023.02.008', 'article-title': 'Drug-induced liver injury with ritonavir-boosted nirmatrelvir: evidence ' 'from coronavirus disease 2019 emergency use authorization adverse event ' 'reporting system', 'volume': '165', 'author': 'Li', 'year': '2023', 'journal-title': 'Gastroenterology'}, { 'key': '10.1016/j.eclinm.2023.102359_bib12', 'article-title': 'Understanding the risk of drug interactions between ' 'ritonavir-containing COVID-19 therapies and small-molecule kinase ' 'inhibitors in patients with cancer', 'volume': '7', 'author': 'Hopkins', 'year': '2023', 'journal-title': 'JCO Precis Oncol'}, { 'issue': '1', 'key': '10.1016/j.eclinm.2023.102359_bib13', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/bcr-2022-252677', 'article-title': 'Pharmacokinetic interaction between verapamil and ritonavir-boosted ' 'nirmatrelvir: implications for the management of COVID-19 in patients ' 'with hypertension', 'volume': '16', 'author': 'Haque', 'year': '2023', 'journal-title': 'BMJ Case Rep'}, { 'issue': '8', 'key': '10.1016/j.eclinm.2023.102359_bib14', 'doi-asserted-by': 'crossref', 'first-page': '1044', 'DOI': '10.1016/j.cmi.2022.03.030', 'article-title': 'Evaluating the risk of drug-drug interactions with pharmacokinetic ' 'boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe ' 'COVID-19', 'volume': '28', 'author': 'Girardin', 'year': '2022', 'journal-title': 'Clin Microbiol Infect'}, { 'issue': '10319', 'key': '10.1016/j.eclinm.2023.102359_bib15', 'doi-asserted-by': 'crossref', 'first-page': '21', 'DOI': '10.1016/S0140-6736(21)02657-X', 'article-title': 'Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 ' 'management', 'volume': '399', 'author': 'Heskin', 'year': '2022', 'journal-title': 'Lancet'}, { 'issue': '2', 'key': '10.1016/j.eclinm.2023.102359_bib16', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2022.106708', 'article-title': 'Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical ' 'efficacy, resistance, relapse, and pharmacoeconomics', 'volume': '61', 'author': 'Focosi', 'year': '2023', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.eclinm.2023.102359_bib17', 'article-title': 'Inhibition mechanism and antiviral activity of an α-ketoamide based ' 'SARS-CoV-2 main protease inhibitor', 'author': 'Chen', 'year': '2023', 'journal-title': 'bioRxiv'}, { 'key': '10.1016/j.eclinm.2023.102359_bib18', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2023.102189', 'article-title': 'Antiviral efficacy of RAY1216 monotherapy and combination therapy with ' 'ritonavir in patients with COVID-19: a phase 2, single centre, ' 'randomised, double-blind, placebo-controlled trial', 'volume': '63', 'author': 'Wang', 'year': '2023', 'journal-title': 'eClinicalMedicine'}, { 'key': '10.1016/j.eclinm.2023.102359_bib19', 'series-title': 'China: WHO coronavirus (COVID-19) dashboard', 'year': '2023'}, { 'issue': '15', 'key': '10.1016/j.eclinm.2023.102359_bib20', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N\xa0Engl J Med'}, { 'key': '10.1016/j.eclinm.2023.102359_bib22', 'series-title': 'Emergency use authorization for paxlovid', 'author': 'Fact Sheet For Healthcare Providers', 'year': '2023'}, { 'key': '10.1016/j.eclinm.2023.102359_bib23', 'doi-asserted-by': 'crossref', 'first-page': '1403', 'DOI': '10.1093/cid/ciac933', 'article-title': 'Efficacy and safety of ensitrelvir in patients with mild-to-moderate ' 'COVID-19: the phase 2b part of a randomized, placebo-controlled, phase ' '2/3 study', 'volume': '76', 'author': 'Mukae', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'issue': '10', 'key': '10.1016/j.eclinm.2023.102359_bib24', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/aac.00697-22', 'article-title': 'A\xa0randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 ' '3C-like protease inhibitor, in Japanese patients with mild-to-moderate ' 'COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a ' 'part', 'volume': '66', 'author': 'Mukae', 'year': '2022', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '2', 'key': '10.1016/j.eclinm.2023.102359_bib25', 'doi-asserted-by': 'crossref', 'first-page': '120', 'DOI': '10.1016/S2213-8587(22)00355-2', 'article-title': 'Risks and burdens of incident dyslipidaemia in long COVID: a cohort ' 'study', 'volume': '11', 'author': 'Xu', 'year': '2023', 'journal-title': 'Lancet Diabetes Endocrinol'}, { 'issue': '6', 'key': '10.1016/j.eclinm.2023.102359_bib27', 'doi-asserted-by': 'crossref', 'first-page': '1191', 'DOI': '10.1002/cpt.2646', 'article-title': 'Recommendations for the management of drug-drug interactions between ' 'the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and ' 'comedications', 'volume': '112', 'author': 'Marzolini', 'year': '2022', 'journal-title': 'Clin Pharmacol Ther'}], 'container-title': 'eClinicalMedicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2589537023005369?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2589537023005369?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2024, 3, 17]], 'date-time': '2024-03-17T10:33:50Z', 'timestamp': 1710671630000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2589537023005369'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 1]]}, 'references-count': 25, 'alternative-id': ['S2589537023005369'], 'URL': 'http://dx.doi.org/10.1016/j.eclinm.2023.102359', 'relation': {}, 'ISSN': ['2589-5370'], 'subject': [], 'container-title-short': 'eClinicalMedicine', 'published': {'date-parts': [[2024, 1]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Leritrelvir for the treatment of mild or moderate COVID-19 without ' 'co-administered ritonavir: a multicentre randomised, double-blind, ' 'placebo-controlled phase 3 trial', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'eClinicalMedicine', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.eclinm.2023.102359', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2023 The Author(s). Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '102359'}